BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36104654)

  • 1. Assessing the Financial Value of Decentralized Clinical Trials.
    DiMasi JA; Smith Z; Oakley-Girvan I; Mackinnon A; Costello M; Tenaerts P; Getz KA
    Ther Innov Regul Sci; 2023 Mar; 57(2):209-219. PubMed ID: 36104654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project.
    Levitan B; Getz K; Eisenstein EL; Goldberg M; Harker M; Hesterlee S; Patrick-Lake B; Roberts JN; DiMasi J
    Ther Innov Regul Sci; 2018 Mar; 52(2):220-229. PubMed ID: 29714515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance.
    Park J; Huh KY; Chung WK; Yu KS
    Transl Clin Pharmacol; 2024 Mar; 32(1):41-51. PubMed ID: 38586122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethics review of decentralized clinical trials (DCTs): Results of a mock ethics review.
    van Rijssel TI; de Jong AJ; Santa-Ana-Tellez Y; Boeckhout M; Zuidgeest MGP; van Thiel GJMW;
    Drug Discov Today; 2022 Oct; 27(10):103326. PubMed ID: 35870693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying Site Burden to Optimize Protocol Performance.
    Florez M; Smith Z; Olah Z; Martin M; Getz K
    Ther Innov Regul Sci; 2024 Mar; 58(2):347-356. PubMed ID: 38191957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment.
    Betcheva L; Kim JY; Erhun F; Oraiopoulos N; Getz K
    Ther Innov Regul Sci; 2023 Sep; 57(5):1081-1098. PubMed ID: 37389795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decentralized clinical trials (DCTs): A few ethical considerations.
    Petrini C; Mannelli C; Riva L; Gainotti S; Gussoni G
    Front Public Health; 2022; 10():1081150. PubMed ID: 36590004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ethics of Decentralized Clinical Trials and Informed Consent: Taking Technologies' Soft Impacts into Account.
    van Rijssel TI; van Thiel GJMW; van Delden JJM;
    Health Care Anal; 2024 May; ():. PubMed ID: 38764063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decentralized Clinical Trials in the Development of Drugs and Biological Products.
    Robinson R; Sacks L
    Ther Innov Regul Sci; 2024 Feb; ():. PubMed ID: 38305983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the divergence in perspectives on clinical trial operations in South Korea during the COVID-19 pandemic: a comparison of a trial site and sponsors.
    Kim YS; Kim A; Lee YS
    Front Med (Lausanne); 2024; 11():1342184. PubMed ID: 38510454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation status and consideration for the globalisation of decentralised clinical trials: a cross-sectional analysis of clinical trial databases.
    Sato T; Mizumoto S; Ota M; Shikano M
    BMJ Open; 2023 Oct; 13(10):e074334. PubMed ID: 37821130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Internet of Medical/Health Things to Decentralized Clinical Trials: Development Status and Regulatory Considerations.
    Sato T; Ishimaru H; Takata T; Sasaki H; Shikano M
    Front Med (Lausanne); 2022; 9():903188. PubMed ID: 35733872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment Perspective.
    de Jong AJ; Shahid N; Zuidgeest MGP; Santa-Ana-Tellez Y; Hogervorst M; Goettsch W; Traore H; de Boer A; Gardarsdottir H;
    Value Health; 2024 Mar; 27(3):294-300. PubMed ID: 38043711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic return of clinical trials performed under the pediatric exclusivity program.
    Li JS; Eisenstein EL; Grabowski HG; Reid ED; Mangum B; Schulman KA; Goldsmith JV; Murphy MD; Califf RM; Benjamin DK
    JAMA; 2007 Feb; 297(5):480-8. PubMed ID: 17284698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Execution of Sustainable Decentralized Clinical Trials.
    Singh P; Burden AM; Natanegara F; Beckman RA
    Clin Pharmacol Ther; 2023 Oct; 114(4):802-809. PubMed ID: 37489911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital health technologies and Alzheimer's disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
    Leroy V; Gana W; Aïdoud A; N'kodo JA; Balageas AC; Blanc P; Bomia D; Debacq C; Fougère B
    Alzheimers Res Ther; 2023 Apr; 15(1):87. PubMed ID: 37106429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs).
    Coyle J; Rogers A; Copland R; De Paoli G; MacDonald TM; Mackenzie IS;
    Trials; 2022 Jul; 23(1):614. PubMed ID: 35907888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Legal, Regulatory, and Practical Issues to Consider When Adopting Decentralized Clinical Trials: Recommendations From the Clinical Trials Transformation Initiative.
    Apostolaros M; Babaian D; Corneli A; Forrest A; Hamre G; Hewett J; Podolsky L; Popat V; Randall P
    Ther Innov Regul Sci; 2020 Jul; 54(4):779-787. PubMed ID: 32557302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic returns of pediatric clinical trials of antihypertensive drugs.
    Baker-Smith CM; Benjamin DK; Grabowski HG; Reid ED; Mangum B; Goldsmith JV; Murphy MD; Edwards R; Eisenstein EL; Sun J; Califf RM; Li JS
    Am Heart J; 2008 Oct; 156(4):682-8. PubMed ID: 18926149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.